🏗️Procurement List Updates
This action adds service(s) to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and deletes product(s) and service(s) from the Procurement List previously furnished by such agencies.
Learn More💼IRS Requests Comments on SIMPLE IRA Plan Forms for Businesses
The Internal Revenue Service, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995. The IRS is soliciting comments concerning Form 5304-SIMPLE, Savings Incentive Match Plan for Employees of Small Employers (SIMPLE)--Not for Use With a Designated Financial Institution; Form 5305-SIMPLE, Savings Incentive Match Plan for Employees of Small Employers (SIMPLE)--for Use With a Designated Financial Institution; Notice 98-4, Simple IRA Plan Guidance.
Learn More💧Water Quality Certification Notice for Oswego Hydro Partners, LP
The Federal Energy Regulatory Commission has notified the New York State Department of Environmental Conservation regarding a request for water quality certification from Oswego Hydro Partners, LP. This notice outlines the timelines for actions on the certification request as per the Clean Water Act, emphasizing the importance of timely responses from regulatory authorities.
Learn More🏥Change in Meeting Notice
The Department of Health and Human Services announces a change in the schedule for the National Advisory Child Health and Human Development Council meeting. The meeting will take place from September 9 to September 10, 2025, at the NIH’s Natcher Building in Bethesda, MD. It will partially be closed to the public.
Learn More🛢️Pipeline Safety
PHMSA is publishing this notice to solicit public comments on a request for one (1) special permit segment extension submitted by Tennessee Gas Pipeline Company, LLC (TGP), a subsidiary of Kinder Morgan, Inc. TGP is seeking relief from compliance with certain requirements in the Federal pipeline safety regulations. At the conclusion of the 30-day comment period, PHMSA will review the comments received from this notice as part of its evaluation to grant or deny the special permit request.
Learn More📊CFTC Notice on Information Collection and Regulatory Impact
In compliance with the Paperwork Reduction Act of 1995 ("PRA"), this notice announces that the Information Collection Request ("ICR") abstracted below has been forwarded to the Office of Information and Regulatory Affairs ("OIRA"), of the Office of Management and Budget ("OMB"), for review and comment. The ICR describes the nature of the information collection and its expected costs and burden.
Learn More💊FDA Guidance on Developing Drugs for Early Lyme Disease Treatment
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of early Lyme disease as manifested by erythema migrans (EM). This guidance finalizes the draft guidance of the same name issued on February 1, 2023.
Learn More⚖️DOT Guidance on Criminal Enforcement and Regulatory Offenses
This notice describes DOT's plans to address regulatory offenses with criminal liability pursuant to the recent executive order on Fighting Overcriminalization in Federal Regulations.
Learn More🚫DEA Revokes Registration of Dr. Bohdan Olesnicky
The Drug Enforcement Administration has revoked the DEA registration of Dr. Bohdan Olesnicky due to his lack of authority to practice medicine in California, following his voluntary surrender of his medical license. This action highlights the necessity for healthcare professionals to maintain state licensure to manage controlled substances legally under federal law.
Learn More💉FDA Classifies X-Ray Attenuation Cream Under Class II Devices
The Food and Drug Administration (FDA, the Agency, or we) is classifying the cream for x-ray attenuation into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the cream for x-ray attenuation's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Learn More